Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 29 May 2025
Reviewer's report:
The manuscript, titled Infliximab for Patients with Moderate to Severely Active Ulcerative
Colitis: An Updated Meta-Analysis of Randomized Controlled Trials, presents a systematic
review and meta-analysis evaluating the efficacy and safety of infliximab (IFX) in treating
moderate-to-severe ulcerative colitis (UC), adhering to Preferred Reporting Items for Systematic
Review and Meta-Analysis Statement (PRISMA).
Observations:
The authors have diligently addressed all critiques, significantly strengthening the manuscript’s
validity, clarity, methodological rigor, transparency, and readability. Thus, the manuscript is
now suitable, fit, and ready for acceptance and publication.
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 29 May 2025
Reviewer's report:
The manuscript, titled Infliximab for Patients with Moderate to Severely Active Ulcerative
Colitis: An Updated Meta-Analysis of Randomized Controlled Trials, presents a systematic
review and meta-analysis evaluating the efficacy and safety of infliximab (IFX) in treating
moderate-to-severe ulcerative colitis (UC), adhering to Preferred Reporting Items for Systematic
Review and Meta-Analysis Statement (PRISMA).
Observations:
The authors have diligently addressed all critiques, significantly strengthening the manuscript’s
validity, clarity, methodological rigor, transparency, and readability. Thus, the manuscript is
now suitable, fit, and ready for acceptance and publication.
Please review this paper.
user
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 29 May 2025
Reviewer's report:
The manuscript, titled Infliximab for Patients with Moderate to Severely Active Ulcerative
Colitis: An Updated Meta-Analysis of Randomized Controlled Trials, presents a systematic
review and meta-analysis evaluating the efficacy and safety of infliximab (IFX) in treating
moderate-to-severe ulcerative colitis (UC), adhering to Preferred Reporting Items for Systematic
Review and Meta-Analysis Statement (PRISMA).
Observations:
The authors have diligently addressed all critiques, significantly strengthening the manuscript’s
validity, clarity, methodological rigor, transparency, and readability. Thus, the manuscript is
now suitable, fit, and ready for acceptance and publication.
assistant